Circulating Tumor DNA and Unique Actionable Genomic Alterations in the Longitudinal Monitoring of Metastatic Breast Cancer: A Case of FGFR2-KIAA1598 Gene Fusion

JCO Precis Oncol. 2023 Jul:7:e2200702. doi: 10.1200/PO.22.00702.

Eleonora Nicolò^{1

2

3}, Laura Munoz-Arcos³, Elena Vagia⁴, Paolo D'Amico⁴, Carolina Reduzzi^{3

4}, Jeannine Donahue^{3

4}, Marco Lorico-Rappa^{4

5}, Maroua Manai^{3

4}, Amir Behdad⁴, Youbin Zhang⁴, Giuseppe Curigliano^{1

2}, Ami Shah⁴, Massimo Cristofanilli^{3

4}

¹ Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy.
² Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
³ Department of Medicine, Division of Hematology-Oncology, Weill Cornell Medicine, New York, NY.
⁴ Department of Medicine-Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL.
⁵ Royal College of Surgeons School of Medicine, Dublin, Ireland.

No abstract available

Publication types